Full-time cancer specialist at the Institut Universitaire du Cancer de Toulouse (IUCT-Oncopole), Dr. Gomez-Roca completed his medical training in 2000 at the University of Buenos Aires with silver medal honors. He trained as internal medicine specialist at Instituto Universitario CEMIC at Buenos Aires (Argentina) and obtained his degree with honors in 2005. He continued his training in Medical Oncology and obtained his diploma at Paris-Sud Medical School (France) in 2007 and completed his Master in Oncology in 2008 at the same university.

During his oncology training, he discovered a passion for early drug development while working under the supervision of Jean-Charles Soria, from 2008 to 2011 at Gustave Roussy. He moved to Toulouse to join Jean- Pierre Delord’s team in 2012 and applied his expertise to help to develop one of the top -three early phase trial programs in France.

Dr. Gomez-Roca is currently Chair of the Clinical Research Unit at IUCT-Oncopole and leader of the Drug Development Unit. His main clinical research interests are early clinical drug development, phase I trials design across solid tumors, innovative methods of evaluation of novel drugs’ clinical activity, personalized medicine and the development of cancer vaccines.

He collaborates at Maha Ayyoub’s lab, looking to understand of the interaction between the colorectal primary tumor’s immune microenvironment and its impact in the systemic immune response to cancer in murine model and translate these findings into better treatment strategies for patients with colorectal cancer.

Dr Gomez-Roca is currently member of ESMO, ASCO and AACR. He contributed to more than 80 peer-reviewed publications including publications as first or second author in the Journal of Clinical Oncology, Annals of Oncology and Science Immunology.

He currently serves as Chair of the Membership Committee (2024-2025) and is a member of the ESMO Council. He is Scientific Chair for TAT ESMO for the period 2026-2028. He also serves as board member at the Société Française d’Immuno-Thérapie du Cancer (FITC) and at the OncoDistinct Network.